Avineuro Pharmaceuticals, Inc. Announces Beginning Of Phase I Clinical Studies Of AVN-211, Potent Small Molecule For Treatment Of Schizophrenia.

Avineuro Pharmaceuticals, Inc. announced an initiation of Phase I clinical studies of AVN-211, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Schizophrenia. The results of Phase I studies are expected to be available in April 2009. Based on these and other results, Avineuro Pharmaceuticals, Inc. plans to advance AVN-211 into Phase II clinical trials in Q2 2009. Avineuro Pharmaceuticals, Inc.

More: continued here

Filed under: Conferences on March 13th, 2009